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Pertussis (whooping cough) is a vaccine-preventable respiratory infection that can 
occur in all ages and can result in life threatening complications, particularly among 
infants.  Although outbreaks have historically occurred cyclically every 2 to 5 years, 
recent outbreaks in the United States have been the largest on record since the 1950's 
despite high vaccination coverage.  The effective control of pertussis is complicated 
by the inability to directly obtain true estimates of incidence and population immunity 
from surveillance data.  Pertussis infections in adults and previously vaccinated 
children often have a mild presentation, which can result in undetected infections.  
Additionally, vaccine coverage is not a direct measure of immune status due to 
imperfect vaccine effectiveness, waning immunity, and natural boosting.  Additional 
data sources and analyses are needed to better understand and ultimately disrupt the 
epidemic cycle of pertussis.  This research (1) tests the feasibility of conducting a 
pertussis seroprevalence study in the University of Minnesota's Driven to Discover 
building at the Minnesota State Fair (2) identifies spatial and spatio-temporal clusters 
of pertussis vaccine exemptions and incidence in Minnesota, and (3) develops a model 
of pertussis transmission in Minnesota to explore the impact of model parameters on 
disease dynamics.  The ability to predict the occurrence of an outbreak based on 
serologic, geographic, and/or demographic characteristics of a population may identify 
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A. GENERAL BACKGROUND 
A1. Clinical Presentation and Transmissibility of Pertussis 
 Pertussis (whooping cough) is a disruptive respiratory infection caused by the 
bacterium Bordetella pertussis.  Bordetella pertussis adheres to epithelial cells that line 
the respiratory tract and releases damaging toxins that interfere with pulmonary 
secretion.
1
  Pertussis illness is characterized by paroxysmal coughing (violent coughing 
spells) that may be followed by vomiting and a high-pitched "whooping" noise upon 
inhalation.  The initial presentation of pertussis is similar to a common cold, consisting of 
a mild cough and runny nose.  This catarrhal stage typically lasts 1 to 2 weeks and is 
followed by a paroxysmal stage, during which time the characteristic symptoms of 
pertussis manifest (Figure 1).  The paroxysmal stage generally lasts 1 to 6 weeks and is 
the most identifiable stage of pertussis illness.
2
  The subsequent convalescent stage may 
persist for months as the cough gradually diminishes in severity during the recovery 
process.  Notably, adults often experience atypical cases of pertussis in which the 
pertussis specific symptoms of the paroxysmal stage are absent.
3,4
  Life-threatening 
complications including pneumonia and encephalopathy can result from pertussis.  
 Transmission of Bordetella pertussis occurs through direct contact with 
respiratory secretions from infected individuals (droplet transmission), which is 
facilitated by coughing and sneezing.  Transmission is possible between individuals of 
any age.  Although contact with contaminated surfaces is not an effective mode of 
transmission, pertussis remains highly contagious with a secondary attack rate of 80%.
1,5
  
The incubation period of pertussis is typically 7 to 10 days, ranging from 4 to 21 days.
1
  
Individuals infected with Bordetella pertussis are considered infectious for 21 days 
2 
 
following cough onset.  Macrolide antibiotics reduce the infectious period to 5 days if an 
appropriate dosage is completed; however, antibiotics may fail to decrease the severity of 
disease if administered after pertussis toxins have damaged respiratory epithelial cells.
6
 
A2. Epidemiology of Pertussis in the United States 
A2.1 Historical Incidence Trends 
 Prior to the vaccine era, pertussis was a common childhood disease that resulted 
in over 100,000 reported cases and an average of 7,300 deaths each year in the United 
States.
7
  The majority of cases occurred in children under the age of 5 years, with infants 
under the age of 1 year at greatest risk of developing life-threatening complications from 
infection.
7
  Outbreaks recurred approximately every 2 to 5 years, with peaks exceeding 
200,000 reported cases (Figure 2).
8
  The introduction of a childhood pertussis vaccine in 
the 1940's drastically reduced pertussis incidence.  Incidence reached a record low in 
1976 with just over 1,000 cases reported nationwide.
8
  However, a noticeable increase in 
reported cases began during the 1990's, a decade in which a modified pertussis vaccine 
and new diagnostic assay were introduced. 
A2.2 Pertussis Vaccines 
 The first pertussis vaccine licensed for use in the United States was the diphtheria 
and tetanus toxoids and whole-cell pertussis vaccine, abbreviated DTP.  Although DTP 
was effective in reducing pertussis incidence, the adverse effects of the vaccine included 
febrile seizures and painful local reactions.
9
  The transition to a safer acellular vaccine, 
DTaP, was initiated in the 1990's with no changes to the timing of vaccine 
administration.
10
  The recommended vaccination schedule remained one dose of pertussis 
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vaccine at 2, 4, 6, 15-18 months, and 4-6 years.
11
  The fourth and fifth doses of DTP were 
replaced with DTaP in 1992, and DTaP replaced all five doses of DTP in 1997.
12
 
 In 2005, Tdap was licensed for use in individuals aged 10 years and older as a 
single dose booster.  Tdap is currently recommended at age 11 or 12 years for children 
who have completed the DTaP vaccination series.
13
  Adults who have not previously 
been vaccinated with Tdap are also recommended to receive the vaccine, as are pregnant 
women in their third trimester of pregnancy.  Notably, both Tdap and DTaP have been 
reported to provide a shorter duration of protection as compared to DTP.  Numerous 
studies have shown that protection against pertussis wanes each year following the fifth 
dose of DTaP.
14,15,16
  Protection provided by Tdap is estimated to last 2 to 4 years.
17,18
  In 
comparison, a review by Wendelboe et al. suggests that protection provided by DTP lasts 




A2.3 Diagnostic Assays 
 Culture and direct fluorescent antibody testing (DFA) were the primary laboratory 
assays used to diagnosis pertussis during the early 1990's.
20
  Faulker et al. examined 
pertussis diagnostic trends in the United States from 1990 to 2012 and found an 
increasing percentage of reported pertussis cased were diagnosed using polymerase chain 
reaction (PCR).  By 2003, PCR had become the most commonly utilized diagnostic test.  
The sensitivity of PCR (>90%) is greater than the sensitivity of DFA (10%-50%), which 
is no longer recommended for diagnostic purposes.
13,20,21,22,23
  During this same time 
frame, the use of culture decreased drastically.  Although culture has near perfect 
specificity, sensitivity is low (<60%) and test results are not rapid.
21,24
  Serology has 
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consistently been utilized infrequently despite the fact that serology has greater 
sensitivity than PCR when testing is performed four weeks past cough onset (Figure 3). 
A2.4 Recent Incidence Trends 
 Recent trends in pertussis incidence should be examined with consideration to 
diagnostic and vaccine changes.  However, shifts in age-specific incidence suggest that 
the resurgence of pertussis is not solely an artifact of detecting a larger percentage of 
underlying infections.  An increasing percentage of cases were reported among 
individuals over the age of 5 years as pertussis began to reemerge.  Nationally, 
adolescents aged 11 to 19 years recorded the highest incidence of pertussis behind infants 
during the outbreak year of 2004 (Figure 4).
8
  By 2012, the largest pertussis outbreak 
year since the 1950's (48,277 cases), incidence rates among children aged 7 to 10 years 
had surpassed incidence rates among adolescents.
8
  These trends parallel changes to the 
vaccine composition and schedule.  Incidence among adolescents as compared to children 
initially decreased following the introduction of Tdap in 2005.  Conversely, 
disproportionately high incidence rates among children aged 7 to 10 years began after the 
first cohorts of children who were completely vaccinated with DTaP reached this age.  
This age group continues to experience high incidence rates due to waning vaccine-
acquired immunity.
14,16
  Thus, although more cases of pertussis are undoubtedly being 
detected due to more sensitive diagnostic methods, deficiencies of the currently 
recommended pertussis vaccines have in part reestablished pertussis as a legitimate 
public health concern. 
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A3. Knowledge Gaps in Pertussis Research 
 The effective control of pertussis is complicated by the incomplete understanding 
of its epidemiology.  The circulation of pertussis within a population cannot be 
adequately assessed using incidence reports, as milder cases of pertussis often remain 
undetected.  Research has shown that pertussis infections in both adults and previously 
vaccinated children are underreported, with missed diagnoses especially common (>90%) 
among adults.
4,25,26
  Aguas et al. hypothesized that as pertussis transmission increases in a 
population, the frequency of mild (undetected) disease increases while severe (detected) 
disease decreases.
27
  Integral to this hypothesis is Aguas et al.'s assumption that immunity 
has a greater effect on reducing disease severity than on reducing transmission.  The 
proposed relationship between disease severity and transmission frequency is thus 
explained by the opportunity for natural boosting (boosting of immunity in partially 
immune individuals exposed to infection) when pertussis circulation is high and the 
parallel opportunity for immunity to wane due to lack of natural boosting when 
circulation is low.  Through model simulations in a hypothetical population with high 
vaccination coverage, Aguas et al. concluded that peak incidence of severe disease (i.e., 
an outbreak year) is expected at intermediate levels of transmission.
27
  Given that mild 
disease is not consistently detected, true peaks in pertussis transmission as compared to 
the observed epidemic cycle are not definitely known. 
 Lavine et al. explored natural immune boosting with the hypothesis that low 
pertussis circulation during the vaccine era explains the recent shifts in age-specific 
incidence.
28
  Model simulations indicated that natural immune boosting requires exposure 
to a lower dose of pertussis antigen than does infection.  Frequent natural immune 
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boosting during the pre-vaccine era among adults and adolescents with primed immune 
systems (memory cells that have previously encountered pertussis antigen) from past 
infection may explain why pertussis historically occurred in young children.  Conversely, 
adolescents and adults may no longer experience the benefits of natural immune boosting 
due to decreased pertussis circulation as the result of high vaccination coverage in 
children.  Lavine et al.'s findings highlight the inadequacy of using vaccination records to 
assess population level immune status, as these records do not capture the effects of 
natural boosting and waning immunity.  Estimating population immunity using routinely 
collected vaccination coverage data (e.g., National Immunizations Survey) is therefore 
deficient.  Additionally, previous research has shown that aggregate measures of 
vaccination coverage at a high level (e.g., statewide) fail to capture local regions of 
unvaccinated individuals, which can be associated with pertussis outbreaks.
29,30
  Thus, 
although outbreaks of pertussis can be reasonably expected to occur every 2 to 5 years, 
knowledge gaps pertaining to unobserved transmission and population immune status 
have prevented the epidemic cycle from being effectively understood and disrupted. 
A4. Pertussis Seroprevalence Studies 
 For a disease such as pertussis, which does not induce lifelong immunity, the 
susceptible population is continually replenished and recurrence is to be expected.
31
  
However, the population susceptibility levels and the level of circulating bacteria at 
which pertussis outbreaks have the opportunity to occur are difficult to establish given 
that estimates of incidence and population immunity obtained from routinely collected 
data are imperfect.  Alternative data sources are needed to assess undetected infections 
and immune status in order to understand their contributions to recurring pertussis 
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outbreaks.  Seroprevalence studies quantify antibody levels among individuals within a 
population, providing access to a measure that can capture the effects of both waning and 
boosting of immunity.  Bordetella pertussis produces multiple antigens, however, only 
the pertussis toxin (PT) antigen is specific to Bordetella pertussis.
32
  The anti-PT IgG 
antibody is accordingly the target of most serologic testing for pertussis.  Inactivated PT 
is also a component of pertussis vaccine, meaning high anti-PT IgG antibody levels are 
evidence of either recent vaccination or recent infection.
23
  Consequently, measuring this 
antibody is a useful tool for assessing both immunity (or susceptibility) and the 
prevalence of undetected infections within a population.  Of note, vaccination history 
must be considered when interpreting positive serologic results. 
 A review by Barkoff et al. examined 44 pertussis seroprevalence studies 
conducted globally.
33
  Many seroprevalence studies have been cross-sectional and 
restricted to one time point, limiting their ability to elucidate temporal trends.
34,35,36
  
Hallander et al. used samples from two non-consecutive time points (1997 and 2007) in a 
seroprevalence study in Sweden.
37
  The first sample was taken before the introduction of 
a childhood vaccination program, and the second sampling occurred ten years after the 
introduction of the vaccination program.  Studies have used this approach to observe 
changes in a population's immunity profile following modifications to a vaccination 
program.  While these types of studies estimate population immunity levels at a given 
point in time, they do not observe how levels vary with respect to the 2 to 5 year 
epidemic cycle of pertussis. 
 Campbell et al. performed a seroprevalence study in Australia using serum 
samples from three time points that coincided with different stages of the pertussis 
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epidemic cycle.  They found that an increased prevalence of undetectable IgG anti-PT 
levels (<5 IU/mL), particularly among young children, preceded an outbreak year.  
However, these time points were non-consecutive (1997, 2002, and 2007).
38
  To our 
knowledge, no study has taken repeated cross-sectional serum samples in consecutive 
years for the full duration of the 2 to 5 year outbreak cycle of pertussis.  Utilizing 
serologic testing to estimate susceptibility and undetected infections in a single 
population over a time span that encompasses both outbreak and non-outbreak years may 
provide insight on demographic-specific trends.
39
  These trends may expose targeted 
opportunities to disrupt the epidemic cycle.  We have identified a novel venue, the 
Minnesota State Fair, in which such a study could potentially be conducted.  For one of 
our aims, we conducted a pilot seroprevalence study to test the feasibility of performing 
annual serologic testing on independent samples of Minnesota residents attending the 
State Fair. 
A5. Pertussis in Minnesota 
 The epidemic cycle of pertussis in Minnesota (Figure 5) has been similar to the 
national epidemic cycle with regard to temporality and age-specific incidence.  
Additionally, statewide incidence rates in Minnesota have been among the highest rates 
nationwide in the past decade.  During the record outbreak year of 2012, Minnesota 
accounted for 8.6% of nationally reported cases despite representing less than 2% of the 
US population.
40
  This disproportionately high burden of disease has occurred in 
Minnesota despite relatively consistent DTaP vaccination coverage that has exceeded 
national coverage.
41
  Intervention strategies identified at the state level have the potential 
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to reduce disease in an afflicted population and may prove to be effective on a larger 
scale given that Minnesota's incidence trends have mirrored national trends. 
 Additionally, Minnesota was selected as a study population due to the foundation 
of pertussis research that has been established using state surveillance data.  Previous 
research conducted using Minnesota data has identified county-level variables associated 
with pertussis incidence, estimated the odds of pertussis each year following receipt of 
the 5th dose of DTaP, and used modeling techniques to estimate population immune 
status and the prevalence of undetected infections among adults and children.
16,26,42
  The 
availability of state-specific estimates contributes to the validity of this research. 
A6. Clustering of Pertussis & Vaccine Exemptions 
 Although statewide DTaP vaccination coverage has been consistently near 85% in 
Minnesota (Figure 6), unvaccinated individuals may not be randomly distributed 
throughout the state.  Previous studies conducted using statewide pertussis vaccine 
exemption data from Michigan and California found 23 and 39 geographic areas, 
respectively, which contained statically significant clusters of children who had DTaP 
exemptions on record at their schools.
29,30
  The relative risk of pertussis in these 
exemption clusters ranged from 1.27 to >30.  Imdad et al. used county level data from 
New York to estimate that the incidence of pertussis increased by 5 cases per 100,000 
population for each 0.1% increase in county exemption rate.
43
  Notably, Feikin at el. 
found that the increased risk of pertussis in areas with high exemption rates is not 
restricted to unvaccinated children.  In a study of Colorado counties, Feikin et al. reported 
that the risk of pertussis among vaccinated children between the ages of 3 years and 18 





Furthermore, demographic and socioeconomic characteristics have been found to be 
associated with pertussis exemption clusters and vaccination clusters.
30
  Thus, conducting 
spatial and spatio-temporal cluster analyses of pertussis incidence and vaccine 
exemptions in Minnesota highlights local areas that may be contributing to outbreaks in 
Minnesota.  Additionally, this analysis sets the groundwork for continued surveillance by 
the Minnesota Department of Health (MDH) in which cluster analyses can be conducted 
as data become available, potentially providing an opportunity for targeted, early 
intervention in areas deemed to be at risk. 
A7. Pertussis Models 
 Although serologic studies and spatial analyses provide additional data beyond 
the data that are obtained through routine surveillance, some parameters are inherently 
unobservable or uncertain and must be estimated.  Modeling offers a means of using 
available data to inform estimates of unknown parameters.  Through calibration, 
observed data (e.g., incidence) serve as targets to which a model is fit by varying 
uncertain parameters over plausible ranges.
45
  In previous research, we used this approach 
to generate estimates of the prevalence of undetected infections and population immunity 
among adults and children in a metropolitan county in Minnesota.
26  Our model was 
limited by its restriction to discretely modeling outbreak years with no simulations of the 
inter-epidemic periods; however, models of pertussis transmission in other populations 
have been successfully implemented over the full epidemic cycle. 
28,46,47
   
 Keeling and Rohani described the trade-off that exists between model accuracy 
and model transparency.  Predictive models require a high degree of accuracy, whereas 





As additional components are incorporated in a model, the model is better able to fit to 
observed data (i.e., more accurate), but the ability to understand the impact of each model 
component on disease dynamic is diminished (i.e., less transparent).  We developed a 
transparent model of pertussis transmission to simulate the epidemic cycle of pertussis, 
incorporating state-specific parameter estimates, where available.  The model can be used 
to explore how the frequency and magnitude of the pertussis epidemic cycle is impacted 
by variation in population-level parameters.  Additionally, the model allows us to 
investigate if individuals with a primed immune system from previous infection or 
vaccination experience a heightened immune response to secondary exposure, as 
suggested by Lavine et al.'s findings that natural immune boosting requires exposure to a 
lower dose of pertussis antigen than does infection.
28
  In combination with serologic data 
and spatial analyses, our modeling study contributes to reducing the knowledge gap that 




B. MANUSCRIPT I 
B1. Objective 
 The study objectives are 1.) To test the feasibility of conducting a pertussis 
seroprevalence study in the University of Minnesota's Driven to Discover building at the 
Minnesota State Fair; 1A.) To quantify pertussis antibody levels in a sample of 
Minnesota residents attending the State Fair to obtain age-specific estimates of 
population susceptibility and the prevalence of undetected infections; 1B.) To create a 
framework for conducting analyses on serologic and survey data by demonstrating 
methods to identify demographic factors associated with pertussis susceptibility and 
undetected infections. 
B2. Introduction 
Seroepidemiologic studies, which measure sera antibody levels produced in 
response to infection and/or vaccination, can be valuable tools for gaining insight on 
population level dynamics of infectious diseases.
39
  Pertussis surveillance in the United 
States consists of case reports from health care providers and laboratories, resulting in an 
underestimation of true incidence by primarily capturing clinically apparent disease.  
Infections that remain undetected have contributed both to the persistence of cyclic 
pertussis outbreaks every 2 to 5 years and to the resurgence of pertussis following near 
elimination in the 1970’s.
8,49
  In various populations, seroepidemiologic studies have 
been conducted to identify adults as a common source of unrecognized transmission.
4,50,51
  
Additionally, seroepidemiologic studies have been used to identify age groups with low 
pertussis antibody levels suggestive of susceptibility due to waning of vaccine-acquired 
immunity.
34
  Because vaccination records cannot capture the unobserved effects of 
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vaccine failure, waning immunity, and natural boosting (boosting of immunity in 
partially immune individuals exposed to infection), serologic data can complement 
vaccination records and provide a more accurate measure of population immunity.
16,28
   
Pertussis seroepidemiologic studies have previously been conducted to identify 
potential areas for public health intervention and to assess vaccine impact on population 
immunity; however, seroepidemiologic studies are commonly restricted to one time 
point, limiting their ability to elucidate temporal trends. 
34,35,51
  To build upon previous 
seroepidemiologic research, one would ideally conduct a study that sampled a single 
population annually in consecutive years over the full epidemic cycle of pertussis.  
Understanding demographic-specific temporal trends in susceptibility and undetected 
infections as they relate to the recurrence of outbreaks would highlight opportunities for 
targeted interventions to disrupt sustained transmission.  However, seroepidemiologic 
studies can be expensive and logistically difficult to conduct.  Consequently, 
seroepidemiologic studies are not routinely used to assess population-based temporal 
trends of infectious diseases.
52
 
The main challenge presented by prospective seroepidemiologic studies that aim 
to monitor changes in population-level immunity over time is collecting sera samples 
from a wide range of age groups drawn from the same population.  Specimen collection 
for serologic testing is generally expensive, time consuming, and labor-intensive. 
Alternatively, relying on stored sera limits our ability to track immunity prospectively 
while monitoring changes in the epidemiology of a given disease in a given time and 
place.  Previous pertussis seroepidemiologic studies that utilized population sampling to 
recruit several hundred participants to study centers have reported enrollment periods 
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approaching one year, a rate that would be taxing for studies seeking to obtain annual 
samples.
35,51
  In a study that measured immunity among school-aged children, Kelly et al. 
reported that the cost per specimen from a population-based random sample was 11 times 
greater than the cost per specimen obtained from residual sera.
53
  Though immediately 
available, samples obtained from residual sera from diagnostic laboratories are subject to 
selection bias and may not be generalizable to a population of interest.
54
  A trade-off 
therefore exists between expenditure of time and money and enrollment of a tailored 
study sample that can provide a complete picture of population level dynamics over time. 
Notably, the National Health and Nutrition Examination Survey (NHANES) has 
been collecting sera specimen annually in the United States since the 1980’s.  However, 
the manner in which the specimens are collected is intended to provide a sample that is 
representative of the nation as a whole.  As such, the sample cannot be assumed to be 
representative of individual states.
55
  This limits the usefulness of these data for 
understanding state-level trends in vaccine-preventable diseases.  Importantly, Rohani et 
al. examined state-specific pertussis incidence rates over time and found that trends 
varied by spatial location.
56
  States may experience varied trends in vaccine-preventable 
diseases due to demographics, state laws, and surveillance practices.
57
  Consequently, 
nationwide samples may be inadequate for certain research questions.  The need exists 
for state-specific venues that can provide an opportunity to collect sera specimens on an 
ongoing basis. 
We hypothesize that state fairgrounds may provide a novel venue for conducting 
seroepidemiologic studies by enabling recruitment of a large number of individuals in a 
short period of time at a relatively low cost.  The Minnesota State Fair attracts between 1 
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and 2 million visitors over a 12 day period each year, with visitors encompassing a large 
age range and representing diverse backgrounds.
58,59
  We hypothesize that this venue will 
allow us to efficiently conduct a pilot pertussis seroepidemiologic study on a sample of 
Minnesota residents consisting of both adults and children.  If this setting is deemed 
feasible following our pilot study, we foresee it facilitating larger seroepidemiologic 
studies for both pertussis and other infectious diseases, with an emphasis on studies 
dedicated to assessing temporal serologic trends in a specific population. 
B3. Research Methods 
B3.1 Study Overview 
 Participants completed a written survey regarding demographic information, 
receipt of pertussis vaccine, and recent history of cough illnesses.  Following completion 
of the survey, participants provided a finger stick blood sample that was submitted for 
serologic testing.  Serologic testing quantified pertussis antibody levels.  Survey results 
were used to determine if elevated antibody levels were induced by recent vaccination or 
recent infection.  Methods for identifying the association between demographic variables 
and serologic results are presented with the understanding that the limited sample size of 
this pilot studies prohibits statistical inference. 
B3.2 Study Population & Sample 
 Because finger sticks are not recommended for children under the age of 1 year, 
the target population of this study was Minnesota residents aged 1 year or older.  
Individuals were eligible for participation if they were at least 1 year old and had a 
primary residence in Minnesota.  Individuals under the age of 18 years were required to 
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be accompanied by an adult.  Enrollment was open to individuals of any gender, race, and 
ethnicity. 
 This research was a pilot study.  As such, our sample size calculation was based 
on budget as opposed to statistical power.  Our budget allowed for the enrollment of 90 
participants.  We used a stratified sampling mechanism based on the following age 
groups: 1-6, 7-17, and 18+ years.  A total of 30 participants were targeted for enrollment 
in each age group.  The bounds of these age groups were based in part on the 
recommended pertussis vaccination schedule, which calls for 5 doses of pertussis-
containing vaccine by the age of 6 years.
60
  As waning of vaccine-acquired immunity has 
been observed following completion of the pertussis vaccination series, we anticipated 
these age groups to differ with respect to estimates of susceptibility and undetected 
infections.
15,16,61
  Although heterogeneity in exposure to vaccination recommendations 
and infection exists in these age groups, particularly among adults, the sample size of this 
study restricted further stratification. 
B3.3 Participant Recruitment 
 Participant recruitment and enrollment occurred over a 3-day period (August 29, 
August 31, and September 1) at the 2016 Minnesota State Fair.  The University of 
Minnesota (UMN) has an existing research facility at the fair, the Driven to Discover 
(D2D) building, in which the study was staged.  In 2016, 12,476 fairgoers participated in 
26 UMN research projects on the fairgrounds.
62
  Two methods were used to recruit 
participants: 1.) a UMN D2D mobile application detailing the nature of the study and 




B3.4 Participant Study Identification 
 Upon enrollment, each participant was assigned a unique four digit study 
identification (ID) number.  Participant study ID and date of birth were recorded on the 
surveys.  Participant study ID, date of birth, and gender were recorded on the laboratory 
submission forms (Appendix A).  No direct identifiers were used to track study 
participants.  Participant contact information was collected and stored separately from 
survey and laboratory results. 
B3.5 Survey 
 Study participants completed a brief, paper-based survey (Appendix A).  To 
distinguish between recent vaccination and recent infection in individuals with elevated 
antibody levels, participants were asked to self-report whether they had received a 
pertussis-containing vaccine (DTaP, DTP, or Tdap) within the past year.  Additionally, 
participants were asked if they had been diagnosed with pertussis or experienced a cough 
illness lasting at least two weeks during the past year.  Individuals reporting a cough 
illness were asked if the coughing occurred in spasms (paroxysmal coughing), if the 
coughing was followed by vomiting (post-tussive vomiting), and if the coughing was 
followed by a high-pitched "whoop" noise (whooping).  The presence of one of these 
symptoms in addition to a two week cough meets the clinical case definition for pertussis 
and was used to determine if an infection was clinically apparent.
63
  The distribution of 
cases that are subclinical vs. clinical is of interest to MDH because it could inform 
potential surveillance strategies. 
 Basic demographic information was collected from participants during the survey.  
These covariates included age, gender, race, ethnicity, education, and home zip code.  
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The response categories for these demographic variables were standardized across all 
studies conducted in the D2D building. 
B3.6 Validity of Survey 
 Miles et al. conducted a systematic review on the validity of different sources of 
immunization reports and found that parental recall of childhood vaccination 
overestimated coverage in 11 of 15 studies included in the analysis.
64
  The percentage 
point difference in vaccination coverage between self report and provider records ranged 
from 5% to 41% in the 11 studies.  Of note, the studies included in this review varied in 
recall time and were not restricted to pertussis vaccines.  Rolnick et al. surveyed adults 
and found that 61% of adults who reported receiving a tetanus booster were unable to 
recall if the booster included a pertussis component (i.e., Td vs. Tdap).
65
  Difficulty in 
distinguishing between these vaccines may result in an overestimation of adult pertussis 
vaccination if previous receipt of Td is mistaken as Tdap.  Although previous research 
suggests that self report of vaccination for our survey will result in false positives, the 
relatively short recall period of one year may attenuate overestimation of vaccine receipt.  
Recall of pertussis symptoms may affect the distribution of cases that are clinical vs. 
subclinical; however; the identification of all cases is dependent on serologic results. 
B3.7 Serologic Testing 
 Serologic testing was conducted on participant blood samples to quantify 
pertussis antibody levels.  A minimum of 50 µL of blood was collected by finger stick 
and allowed to clot for 30 minutes at room temperature.  Specimens were centrifuged on 
site in Serum Separator Tubes (SST) for 90 seconds at 6,000 to 15,000 g to isolate serum 
from blood cells.  Centrifuged samples were immediately refrigerated.  Specimens were 
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transported on ice to the Minnesota Department of Health Public Health Laboratory 
(MDH-PHL) for testing at the end of each day.  Antibody levels were quantified using an 
IgG anti-PT ELISA assay that was developed by the Centers for Disease Control and 
Prevention and validated at MDH-PHL for use with acute or convalescent serum 
specimens.
61
  This assay measures antibody levels against pertussis toxin, a pertussis-
specific antigen that is produced by the bacterium Bordetella pertussis and is a 
component of pertussis vaccines.  We categorized antibody levels according to 
commonly used cut-off values, with a concentration above 62.5 IU/mL indicating 
infection or vaccination within the past year (Table 1).
33
  An undetected infection was 
defined as a participant who met all of the following criteria: 1.) had antibody levels 
>62.5 IU/mL; 2.) reported no pertussis vaccination within the past year; 3.) reported no 
diagnosis of pertussis by a healthcare provider within the past year.  As the cut-off value 
that we are using to indicate a positive serology laboratory result is lower than the 
typically used MDH cut-off value (100 IU/mL), MDH did not conduct case 
investigations on individuals who tested positive in this study.  The higher cut-off value 
used in routine MDH testing restricts case investigations to recent infections in which 
public health intervention is timely, whereas this study was assessing infections and 
vaccinations over the past year.  Participants who reported symptoms consistent with 
pertussis received MDH recommendations on appropriate treatment and follow-up, if 




B3.8 Validity of Serologic Testing 
 Pertussis IgG antibody responses are considered to be more sensitive than both 
IgA and IgM responses. 
23,66
  Serologic testing for pertussis is therefore typically 
restricted to quantifying IgG antibody levels.  Many commercial laboratories perform 
single-sample serologic testing for pertussis; however, cut-off values for antibody levels 
are not standardized.  Guiso et al. compared results from serologic studies performed in 
three different countries and concluded that the IgG anti-PT cut-off value which 
optimizes sensitivity and specificity is likely between 60 and 75 IU/mL, with a value of 
62.5 IU/mL generally accepted to indicate infection or vaccination within the past year.
67
  
Sensitivity and specificity at this cut-off value are estimated to be 80% and 95%, 





The primary aim of this study was to determine the feasibility of conducting a 
rapid seroepidemiologic study in the unique setting of a fairground.  We were able to 
reach our total enrollment goal and obtain specimens that were satisfactory for testing 
(i.e., sufficient volume, integrity uncompromised).  We conservatively anticipated 
processing 5 participants per hour during each of our 3 allotted study shifts on the 
fairgrounds.  Each shift lasted 6 hours, totaling an expectation of 30 participants per day.  
We easily exceeded our projected rate of enrollment on the first day of the study with 
over 50 study participants.  During the remaining 2 days of the study, we intentionally 
slowed recruitment efforts, as our study budget restricted testing to 90 specimens.  Based 
on recruitment numbers from this pilot study, projected enrollment for a future 
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seroepidemiologic study is shown in Table 2.  Note that the projected numbers are based 
on conducting a study during 1 of the 2 available 6 hour shifts on the fairgrounds each 
day.  Enrollment numbers would be greater if both shifts were used. 
We over-enrolled 14 participants to ensure that we would have 90 testable 
specimens if any specimens were deemed unsatisfactory for testing.  Children aged 1 to 6 
years were difficult to enroll without active recruitment by study staff, which resulted in 
the decision to allow a larger percentage of participants in the older age groups.  The 
demographics of study participants are shown in Table 3.  We compared the 
demographics of study participants to Minnesota demographics from the 2016 American 
Community Survey to assess if our sample was representative of the state population.  
Study participants were primarily white and not Hispanic or Latino, similar to the state's 
racial and ethnic profile.  Compared to the Minnesota population, study participants were 
more likely to be female and to reside within the seven county metro area.   
The distribution of serologic results is shown in Figure 7.  The prevalence of 
undetectable antibody levels was 53.8% (95% CI: 26.7%, 80.9%) in the 1-6 year age 
group, 72.3% (95% CI: 59.6%, 85.1%) in the 7-17 year age group, and 23.3% (95% CI: 
8.2%, 38.5%) in the ≥18 year age group.  Self-report of pertussis vaccination in the past 
year among individuals with undetectable antibody levels was 42.9% (95% CI: 6.2%, 
79.6%), 14.7% (95% CI: 2.8%, 26.6%), and 14.3% (95% CI: 0.0%, 40.2%) in the 1-6, 7-
17, and ≥18 year age groups, respectively.  Of note, elevated antibodies suggestive of 
recent infection were found among two adults, neither of whom reported vaccination, 




The results of this pilot study demonstrate that a fairground setting is a viable 
option for efficiently conducting seroepidemiologic studies within the scope of a state 
population.  Our ability to enroll participants and collect satisfactory specimens suggests 
that larger seroepidemiologic studies with 1,000 to 2,000 participants could feasibly be 
completed over the course of 12 days.  Specifically, a fairground setting could facilitate 
annual population sampling to monitor serologic trends in a single population over time.  
Contrary to relying on residual sera or NHANES samples, our specimen collection 
allowed for sampling of tailored subgroups and collection of disease-specific variables 
(i.e., self-report of symptoms, vaccination history, and clinical diagnosis) via participant 
surveys. 
The limited sample size of our pilot study prohibits statistical inference; however, 
our data suggest that children may have a higher prevalence of undetectable pertussis 
antibody levels than do adults.  Heightened susceptibility among children as compared to 
adults has been observed in seroepidemiologic surveys in other countries.
37,38
   
Specifically, Campbell et al. observed an increased prevalence of undetectable antibody 
levels among children preceding a record outbreak in Australia. 
38
  Observing temporal 
variation in the prevalence of undetectable antibody levels among children despite 
consistent vaccination coverage may be suggestive of a change in the circulation of 
Bordetella pertussis within a population.  Our pilot study demonstrates that we could 
feasibly use the Minnesota State Fair to obtain annual sera samples over the course of a 
full epidemic cycle in an attempt to find a surveillance measure that is indicative of an 
impending outbreak year.  Additionally, demographic-specific trends interpreted in 
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combination with routine surveillance data may highlight a subgroup in which targeted 
intervention could disrupt sustained transmission between outbreak years.  Although cut-
off values for serologic pertussis testing are not definitive, focusing on relative changes 
over time in a single population will produce directly comparable results that should be 
subject to less uncertainty as we use seroepidemiologic studies to better understand local 
dynamics of the epidemic cycle of pertussis.
33
 
In addition to providing estimates of population susceptibility and infection 
prevalence for infectious diseases, large seroepidemiologic studies conducted on 
fairgrounds could be used to efficiently monitor vaccine impact.
37
  Serologic data can 
inform public health policy by identifying susceptible subgroups that may benefit from an 
adjustment to vaccine recommendations.  Importantly, the fixed timing of the state fair 
each year would control for seasonal effects.
68
  Although our study focused on pertussis, 
this unique opportunity for serologic surveillance could be extended to other infectious 
diseases, including influenza.  Miller et al. used sera samples collected in two consecutive 
years to establish an immunity profile in an English population before and after a wave of 
influenza infection.
69
  The authors concluded that continued serologic studies would be 
beneficial to understanding the epidemiology of specific subtypes and providing data to 
inform parameters for prediction models.  State fairgrounds present a logistically simple 
solution for such sustained research. 
We acknowledge that our study sample may not be representative of the state of 
Minnesota.  Metropolitan residents were overrepresented, which is not unexpected given 
that the fairgrounds are located in a metropolitan county.  Future studies could stratify 
enrollment based on county of residence or adjust the target population to the seven 
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county metro, which contains over half of the state’s population.  Additionally, selection 
bias in our study is possible if health status or vaccination status impacted participation.  
Under this assumption, we would expect participants to be less likely to have pertussis 
and more likely to be vaccinated as compared to non-participants.  However, since we 
were assessing pertussis illness over the past year with serologic results, we would still 
expect to capture a high percentage of previously infected individuals.  Of note, we did 
not meet our enrollment goal for children under the age of 6 years.  Enrolling young 
children required active recruitment by study staff stationed outside of the research 
building, and this age group was not preferentially targeted for enrollment until the last 
day of the study.  Studies seeking to enroll participants in this age group, or from any 
specific subgroup, would benefit from targeted recruitment for the duration of the study.   
Our study’s self report of vaccination within the past year would benefit from 
verification with vaccine records.  Future studies could obtain pertussis vaccination 
records from the Minnesota Immunization Information Connection (MIIC), an electronic 
immunization database maintained by MDH.  MIIC records, which contain date of 
vaccination and vaccine formulation, would allow time since vaccination to be 
considered in analyses.  Studies with a larger sample size would also benefit from further 
stratifying age groups to capture the effect of the recommended dose of Tdap at ages 11 
to 12 years.  The age group of 7 to 17 years contains ages in which susceptibility would 
be expected to be both low (immediately after Tdap) and high (both prior to Tdap and 
when immunity from Tdap has waned).  This heterogeneous grouping may obscure 
results in this age group. 
25 
 
We recognize that at this time, Minnesota may be uniquely positioned to leverage 
such an opportunity due to the existence of UMN’s D2D building dedicated to staging 
research projects on the state fairgrounds. Additionally, Minnesota had the second 
highest total attendance among state fairs in 2016.
70
  To our knowledge, no other state is 
utilizing a fairground setting to access a sample of residents for research purposes, 
specifically serological surveillance.  Minnesota can serve as a model for implementing 
this novel sampling mechanism that bypasses many of the logistical challenges of 
seroepidemiologic studies. 
B6. Conclusion 
In conclusion, the results of this pilot study demonstrate that state fairgrounds can 
be utilized to recruit participants for seroepidemiologic studies with minimal expenditure 
of time or money.  Our results raise the possibility of conducting routine population-
based seroepidemiologic studies to supplement traditional public health surveillance in 
estimating disease prevalence, monitoring vaccine impact, and identifying at-risk groups. 




C. MANUSCRIPT II 
C1. Objective 
 The study objectives are 2.) To identify spatial and spatio-temporal clusters of 
pertussis vaccine exemptions and pertussis incidence in Minnesota; 2A.) To determine 
the association between the geographic location of exemption clusters and pertussis 
clusters in Minnesota; 2B.) To identify demographic and socioeconomic factors 
associated with pertussis clusters and exemptions clusters in Minnesota. 
C2. Introduction 
The association between non-medical vaccine exemptions and the occurrence of 
vaccine-preventable diseases, particularly pertussis, has drawn increased attention in 
recent decades.  Pertussis incidence rates in the United States have risen to levels 
previously observed in the 1950’s, with outbreaks continuing to occur cyclically every 2 
to 5 years (Figure 2).
8
  Numerous factors have been attributed to the resurgence of 
pertussis, including waning of vaccine-acquired immunity, bacterial evolution, and 
parental refusal of childhood vaccines.
56,71,72
  Vaccine refusal is regulated at the state 
level by permissible exemptions to school immunization requirements.  All states allow 
medical exemptions for vaccine contraindications, and a subset of states allow 
nonmedical exemptions due to religious and/or philosophical beliefs.
73
  Non-medical 
exemptions to the childhood pertussis vaccine, DTaP, have been associated with an 
increased risk of pertussis at both the individual and population levels.
29,30,43,44,72,74,75
  The 
risk of a non-medically exempt child contracting pertussis has been estimated to range 
from 6 to 23 times the risk of a vaccinated child.
44,75
  From a population perspective, 
census tracts located within a cluster of non-medical exemptions have been estimated to 
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be 2 to 3 times more likely to overlap with pertussis clusters as compared to census tracts 
located outside of exemption clusters.
29,30
  Clusters in this context are geographic areas 
with more exemptions/pertussis cases than would be expected if their occurrence was 
proportionate to the population at risk.  To date, the risks associated with clusters of 
DTaP exemptions have been derived from research restricted to non-medical exemptions 




The focus of cluster analyses on non-medical exemptions has justifiably been 
driven by the opportunity for public health intervention, as vaccine refusal is the result of 
personal choice rather than medical contraindication.  Studies that identify geographic 
overlap of areas with high non-medical exemption rates and areas with high pertussis 
incidence provide compelling data to combat vaccine refusal.  However, medical 
exemptions, despite being less prevalent, also contribute to the susceptible population.  
For analyses that strictly aim to assess population risk, the distinction between exemption 
categories disregards a subset of susceptible individuals.  Moreover, a recent study of 
school immunization data from California illustrated that this distinction is subject to 
misclassification.
76
  Under a similar rationale, fully understanding the impact of 
exemption clusters on an entire population requires the inclusion of adults in the 
definition of persons at risk of pertussis, as transmission can occur between individuals of 
any age.
1
  State health departments, in particular, are in a position to use this broader 
definition to further explore relationships between exemption status and incidence trends. 
Schools report exemption data to state health departments at a fixed time each 
year as part of annual immunization reports.  For example, immunization reports in 
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Minnesota are due by December 1 each year.  These reports offer state health 
departments the opportunity to assess the association between DTaP exemption clusters 
and overlapping pertussis clusters on a recurring basis.  Notably, previous cluster 
analyses have aggregated exemption data over multiple years under the rationale that 
exemption rates within schools are relatively stable over time.
29,30
  Such studies cannot 
detect if a temporal pattern exists between cluster overlap (or non-overlap) and the cyclic 
occurrence of pertussis outbreaks every 2 to 5 years.
8
  To expand upon previous research, 
we measured the association between DTaP exemptions and pertussis incidence with 
consideration of the following 1.) inclusion of both non-medical and medical exemptions 
2.) inclusion of all ages in the population at risk of pertussis infection, and 3.) no 
temporal aggregation of annual exemptions.  We implemented these methodological 
adjustments using immunization data from Minnesota kindergartners and incidence data 
from the Minnesota Department of Health (MDH).  By routinely conducting these 
analyses, MDH could potentially use exemption data reported each December to forecast 
communities at increased risk of pertussis in the upcoming calendar year.  The ultimate 
goal of these analyses would be to reduce transmission in high risk areas by modifying 
prevention efforts (e.g., expand recommendations for testing) when cases are first 
identified.  
C3. Research Methods 
C3.1 Study Overview 
 This study consisted of cluster analyses performed using Minnesota school-
reported vaccine exemption data and pertussis surveillance data.  Geographic areas which 
contained a greater number of pertussis cases or a greater number of vaccine exemptions 
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than was expected based on population density were identified.  We assessed the overlap 
of identified exemption clusters and pertussis clusters to determine if geographic areas 
with exemption clusters are associated with increased pertussis incidence.  Using 
demographic and socioeconomic data aggregated at the census tract level, we assessed 
population characteristics inside identified clusters as compared to outside clusters. 
C3.2 Data Sources 
C3.2.1 Exemption data 
 Under Minnesota law, children enrolled in school must receive either vaccinations 
consistent with medically acceptable standards or an exemption to vaccination.
77
  For 
children entering kindergarten, the pertussis vaccination requirement consists of having 
completed five doses of DTaP, with four doses considered acceptable if the fourth dose 
was administered after the age of four years.  Exemptions from immunizations are 
allowed if 1.) a health care provider submits a signed note to the school indicating a 
medical contraindication or laboratory confirmation of existing immunity or 2.) a legal 
guardian submits a notarized statement of conscientious objection.
78
  Schools are required 
to submit an Annual Immunization Status Report (AISR) to MDH by December 1 each 
year.  The AISR provides school-specific counts of the number of enrolled kindergartners 
and the number of kindergartners who have received an exemption (either medical or 
non-medical) to vaccination.
78
  Reported exemptions are vaccine specific.  Because 
addresses for each exempt individual are not reported with AISR data, we used school 
addresses as a proxy for home address to geocode exemptions using a composite 
addresses locator in ArcMap 10.4 (Esri, Redlands, California).  The composite locator 
matched school addresses against a street locator, then subsequently against a ZIP Code 
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locator if a street level match was not found. Geocoded AISR data were aggregated to 
produce annual counts of kindergartner enrollment and DTaP exemptions by census tract.  
Minnesota contains 1,338 census tracts. 
C3.2.2 Case Data 
  Confirmed and probable pertussis cases with cough onset between 2013 and 2016 
were identified using the Minnesota Electronic Disease Surveillance System (MEDSS), 
an MDH database that houses case investigation data for reportable diseases.  The 
Minnesota Communicable Disease Rule, Chapter 4605 requires that health care providers 
and other entities report suspected cases of pertussis to MDH within one working day.
79
  
MDH subsequently conducts case investigations on all suspected cases of pertussis.  
Clinical, demographic, and epidemiologic information are collected from both the case 
(or case's parent) and the case's provider, if applicable.  The Health Insurance Portability 
and Accountability Act (HIPPA) permits providers to share patient medical history 
without patient authorization when the information is related to the case investigation of a 
reportable disease.
80
  Consequently, the clinical information needed to define an illness as 
pertussis can be collected and entered into MEDSS regardless of the outcome of an 
interview attempt with a suspected case. 
 Confirmed and probable cases of pertussis are defined based on information 
collected during the MDH case investigation.  A case of pertussis is considered 
confirmed if symptoms meet the clinical case definition of pertussis and 1.) the diagnosis 
is laboratory confirmed by culture or polymerase chain reaction or 2.) the case had 
contact with a laboratory confirmed case.
63
  The clinical case definition of pertussis is 
defined as a cough illness lasting at least two weeks with either paroxysms of coughing, 
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inspiratory whooping, and/or post-tussive vomiting as reported by a clinician or the 
case.
63
  A case of pertussis is considered probable if it meets the clinical case definition 
of pertussis but does not meet the additional criteria needed to be confirmed.
63
  The 
confirmed and probable case definitions for pertussis did not change between 2013 and 
2016.  Case addresses were geocoded using a composite address locator in ArcMap that 
matched addresses against a street locator, then subsequently against a ZIP Code locator 
if a street level match was not found.  Geocoded cases were aggregated to produce counts 
of cases by census tract and cough onset date. 
C3.2.3 Demographic and Socioeconomic Data 
  Demographic and socioeconomic variables were obtained from 2010 Census 
data.  All variables were aggregated at the census tract level.  These variables include 
race, ethnicity, highest level of education, median household income, and average 
household size (number of residents per household).  Previous research has shown that 
affluence (measured by kindergarten tuition) is associated with vaccine refusal, and 
possessing at least a college level education is associated with vaccine uptake.
81,82
  
Variables that impact the number and type of contacts that individuals have (e.g., average 
household size) have been shown to be associated with pertussis incidence.
42
 
C3.3 Exemption Cluster Identification 
 SaTScan software (Information Management Services, Inc., Boston, 
Massachusetts) was used to identify spatial clusters of exemptions.  Clusters in this 
context are geographic areas with more exemptions than would be expected if their 
occurrence was proportionate to the population at risk.  The population at risk of 
exemptions was defined as Minnesota kindergartners, estimated from AISR data.  To 
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assess spatial clustering of exemptions, observed data (i.e., geocoded exemptions 
aggregated by census tract) were compared to data simulated from a Poisson distribution.  
The null hypothesis was that exemptions were randomly distributed over space.
83
  Each 
school year of AISR data (2012-2013, 2013-2014, 2014-2015, 2015-2016) represented a 
distinct period within which exemption clusters were identified.  This design allowed for 
the assessment of geographic overlap of exemption clusters in a given school year and 
pertussis clusters occurring in the following calendar year.  Because AISR data are 
reported annually and do not contain a more granular time component, the exemption 
cluster analyses were strictly spatial. 
C3.4 Pertussis Cluster Identification 
SaTScan software was used to identify space-time clusters of pertussis cases with 
cough onset between 2013 and 2016.  Clusters in this context were geographic areas and 
time periods with more pertussis cases than would be expected if their occurrence was 
proportionate to the population at risk and the length of the time period.  The population 
at risk of pertussis was defined as Minnesota residents of all ages, estimated from 2013 
through 2016 American Community Surveys.  Because vaccinated individuals may be at 
risk of pertussis due to primary vaccine failure or waning immunity, they were included 
in the population at risk.  To assess space-time clustering of pertussis cases, observed 
data (i.e., geocoded pertussis cases aggregated by census tract and cough onset date) were 
compared to data simulated from a Poisson distribution.  The null hypothesis was that 





C3.5 SaTScan Statistics 
 SaTScan generates circular scan windows to compare observed and expected data 
in a given geographic area.  In our spatial and space-time analyses, the center of each 
window was a grid point defined by the centroid of census tracts.  Scan windows vary in 
size and were allowed to include up to 50% of the population at risk.
83
  This limit is a 
recommended SaTScan setting that allows both large and small clusters to be identified.  
The radius of the scan windows can be restricted by geographic area; however, a 
population-based restriction is recommended when the size of clusters are uncertain.
83
  In 
space-time analyses, SaTScan scan windows have an added component of height to 
represent time.  With this added dimension, the scan window becomes a cylinder.
83
  
Cough onset served as the time variable in our space-time analysis of pertussis cases.  
The temporal window was limited to include at most 50% of the study period and had a 
precision of one month. 
SaTScan generates scan windows with varying centers and radiuses to assess for 
clustering.  The scan window that produces the most likely cluster is the scan window 
which maximizes the likelihood function for the Poisson model. The likelihood function 
for a given scan window is defined as: 
 
 




   
      
 
   
 
where C is the total number of cases/exemptions, c is the observed number of 
cases/exemptions within the window, and E[c] is the expected number of 
cases/exemptions within the scan window under the null hypothesis.
83
  Thus, the 
likelihood is a product of functions of observed to expected ratios within and outside the 
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scan window.  An indicator variable in SaTScan can restrict analysis to clusters of high 
rates only (i.e., scan windows must contain more cases/exemptions than expected).  The 
likelihood equals 1 when observed data match expected data both inside and outside the 
scan window.  As the number of observed cases/exemptions within the scan window 
exceeds the number of expected cases/exemptions, the likelihood increases. 
 Monte Carlo simulations were used to generate data sets under the null 
hypotheses.  For both the spatial and space-time analyses, the maximum likelihood from 
the observed data was compared to the maximum likelihoods from the simulated data.  
For example, with 999 data sets simulated under the null hypothesis, the null hypothesis 
was rejected at the α = 0.05 level if the maximum likelihood from the observed data 
ranked among the 50 highest simulated likelihoods.
83
  The rejection of the null hypothesis 
for a given cluster was independent of the location of cases/exemptions outside of the 
cluster, as the observed versus expected numbers of cases/exemptions within the window 
was being compared.
83
  We retained only the statistically significant clusters that did not 
overlap with a previously reported cluster. 
C3.6 Regression analyses 
We used logistic regression to assess the geographic overlap of spatial clusters of 
exemptions among kindergartners in a given school year and space-time pertussis clusters 
among individuals of all ages with a cluster start date in the following calendar year (e.g., 
2012-2013 school year exemption clusters based on December 2012 ASIR data in 
relation to pertussis clusters with start date in 2013).  From the cluster analyses, each 
census tract was assigned a value of 1 or 0 indicating if the centroid of the census tract 
was located inside or outside of a pertussis cluster.  The same assignment was made to 
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census tracts for exemption clusters.  The logistic regression odds ratio represented the 
odds of a census tract within an exemption cluster being located in a pertussis cluster 
compared to the odds of a census tract outside an exemption cluster being located in a 
pertussis cluster.  This odds ratio was calculated using both an unadjusted model and a 
model that was adjusted for demographic variables obtained from 2010 census data 
aggregated at the census tract level.  We used univariate logistic regression to identify 
demographic variables associated with census tracts located in pertussis clusters and with 
census tracts located in exemption clusters.  Demographic variables included in this 
analysis represented race, ethnicity, education, household income, and average household 
size (number of residents per household).  Regressions were performed with Stata 13.1 
(StataCorp LP, College Station, Texas). 
C4. Results 
C4.1 Geocoding Results 
AISR data were reported by a total of 1,285 schools between the 2012-2013 and 
2015-2016 school years, resulting in 4,706 school years of exemption data.  AISR 
response rates from Minnesota schools ranged from 95.7% to 97.8% during the study 
period.
84
  A total of 45 (1.0%) school years of exemption data were excluded from the 
analysis due to school addresses that could not be geocoded.  Of the 3,431 confirmed or 
probable cases of pertussis reported to MDH during the study period, 24 (0.7%) were 
excluded from the analysis due to an insufficient address for geocoding.  Twenty-one 
(0.6%) of the 3,407 geocoded cases were geocoded to the zip code level after failing to 
match an address on the street level.  The final data set used for analysis consisted of 
4,661 school years of exemption data and 3,407 pertussis cases.  The distribution of 
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geocoded cases across calendar years was 858 (25.2%) in 2013, 945 (27.7%) in 2014, 
593 (17.4%) in 2015, and 1011 (29.7%) in 2016. 
C4.2 Exemption Clusters 
A total of 6 spatial exemption clusters were observed in the 2012-2013 school 
year, 8 in 2013-2014, 4 in 2014-2015, and 5 in 2015-2016 (Table 4).  Census tract 
demographic variables positively associated with increased odds of being located in an 
exemption cluster were the percentage of households with income over $100,000 and 
average household size.  The percentages of non-white and Hispanic residents and the 
percentage of residents with less than a high school degree were inversely associated with 
the odds of being located in an exemption cluster. 
C4.3 Pertussis Clusters 
Nine spatiotemporal clusters of pertussis cases spanning 505 (37.7%) census 
tracts were identified during the study period (Table 5).  The 2013 and 2016 calendar 
years each contained 4 pertussis clusters.  One pertussis cluster had a start date in 2015, 
with cases that extended into 2016.  Additionally, one of the 2013 pertussis clusters 
included cases that extended into 2014.  Census tract demographic variables associated 
with statistically significant increased odds of being located in a pertussis cluster were the 
percentage of non-white residents, the percentage of households with income over 
$100,000, and average household size (Table 6).  The percentage of residents in a census 
tract with less than a high school degree was inversely associated with the odds of being 
located in a pertussis cluster. 
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C4.4 Overlap of Pertussis Clusters with Exemption Clusters 
Figure 8 shows census tracts with exemption clusters identified from annual 
immunization school reports and pertussis clusters with onset during the following 
calendar year.  The unadjusted odds ratio for 2012-2013 exemption clusters and 2013 
pertussis clusters was 9.83 (95% CI: 6.05, 15.97), compared to 8.64 (95% CI: 6.07, 
12.28) for 2015-2016 exemption clusters and 2016 pertussis clusters.  The adjusted odds 
ratios for these years were 10.01 (95% CI: 5.97, 16.79) and 9.81 (95% CI: 6.62, 14.55), 
respectively.  The odds ratio for 2014-2015 exemption clusters and 2015 pertussis 
clusters, 0.35 (95% CI: 0.08, 1.58), was not statistically significant.  As no pertussis 
clusters with a start date in 2014 were observed, no association was calculated using the 
2013-2014 school year exemption data. 
C5. Discussion 
Our results suggest that temporal differences may exist in the relationship 
between geographic clustering of DTaP exemptions and overlapping clusters of pertussis 
cases in the subsequent year.  Specifically, the strength of this association may be 
dependent on the 2 to 5 year epidemic cycle of pertussis.  Minnesota experienced a record 
outbreak year in 2012 with over 4,000 reported pertussis cases.  In contrast, the number 
of reported pertussis cases dropped to 595 in 2015.  These 2 years represented high and 
low points of the epidemic cycle in Minnesota, respectively.  The 2012 outbreak 
extended into 2013, which was of 1 of 2 calendar years in our analysis in which we 
observed a statistically significant overlap of pertussis clusters with exemption clusters.  
Statistically significant overlap was also observed in 2016, a year which represented a 
nearly twofold increase in pertussis incidence from the previous year.  These results 
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suggest that exemption clusters may not be predictive of pertussis clusters in years which 
represent low points of the epidemic cycle of pertussis, as herd immunity may be high 
enough to combat the risk posed by exemption clusters.  This notion is supported by the 
serologic finding from Campbell et al. that high population prevalence of undetectable 
antibody levels (i.e., susceptibility) among children immediately preceded an outbreak in 
Australia, while low prevalence of undetectable antibody levels was observed during a 
lull in the epidemic cycle.
38
  Seroprevalence studies conducted between outbreak years 
may complement cluster analyses in identifying areas and/or demographics that 
contribute to sustained transmission. 
Notably, previous cluster analyses of a similar nature have reported smaller odds 
ratios.  Omer et al. aggregated kindergarten exemption data from Michigan between 1991 
and 2004 and restricted pertussis cases to individuals aged 18 years or younger in an 
analysis that produced an odds ratio of 2.7.  Atwell et al. aggregated kindergarten 
exemption data from California between 2005 and 2010 and estimated an odds ratio of 
2.47.  In our analysis, odds ratios for the two statistically significant years (9.83, 8.64) 
were considerably larger than these estimates.  The stronger association observed in our 
study may be due in part to the inclusion of medical exemptions and pertussis cases of all 
ages, which we consider an appropriate method for assessing overall population risk.  
Medical exemptions, however, only accounted for approximately 4% of all exemptions 
during the study period.  More so, our results suggest that temporally aggregating 
exemption data to arrive at a single risk estimate may diminish the observed association 
between exemption clusters and pertussis clusters in some years (i.e., high points of the 
epidemic cycle) while overestimating the association in other years (i.e., low points of the 
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epidemic cycle).  To our knowledge, this study is the first to measure the association 
between pertussis clusters and DTaP exemption clusters on an annual basis. 
Our findings regarding predictors of pertussis clusters are consistent with a 
previous ecological analysis that assessed factors associated with increased pertussis rates 
in Minnesota.  At the county level, Iroh Tam et al. similarly found educational attainment 
of less than a high school degree to be inversely associated with pertussis incidence rates, 
while income and average household size were positively associated with pertussis 
incidence rates.
42
  Our results are also consistent with research that found vaccine refusal 
or delay to be positively associated with non-Hispanic white race, educational attainment, 
and household income.
85
  Interestingly, the percentage of non-white residents in a census 
tract was associated with decreased odds of being in an exemption cluster and increased 
odds of being located in a pertussis cluster.  This disparity could be reflective of access to 
healthcare, as white children in the United States are more likely to have a source of 
usual care than are non-white children.
86
  Therefore, although census tracts with a higher 
percentage of non-white residents may be less likely to experience exemption clusters, 
the ability to contain pertussis outbreaks in these census tracts may be hindered by lack of 
access to healthcare providers for testing and treatment. 
We acknowledge that our study design presents limitations.  Exemption status is a 
proxy for susceptibility and is not necessarily reflective of true susceptibility status.  
Schools may incompletely report exemptions, and conversely, the report of an exemption 
does not necessarily mean that a child is completely unvaccinated (i.e., a child may 
partially complete the five dose DTaP series).  For the purpose of this analysis, we 
assumed that exempt children are not up-to-date on pertussis vaccines.  Vaccination 
40 
 
history would be required to determine the effect of partial vaccination verses no 
vaccination on clustering of pertussis incidence. 
 Of note, our analysis represented pertussis cases occurring during a single 
epidemic cycle and consisted of cases that were reported to MDH.  Pertussis infections, 
particularly among adults, often remain undetected due to non-specific clinical 
presentation.
87
  We previously estimated that approximately 90% of pertussis infections 
in adults remain undetected.
26
  In future research, serologic testing and models can be 
used to address uncertainty regarding the prevalence of undetected infections.  However, 
we would not expect detection of pertussis to differ differentially with respect to 
clustering of census tract level exemptions.  Importantly, census tract level observations 
may not hold true at the individual level. 
Identified clusters are restricted by census tract boundaries and should not be 
interpreted as exact locations.  The impact of aggregating individual data for cluster 
analysis is depicted in Figure 9.  Because school address was used as a proxy for home 
address for exemptions, exempt individuals may not have resided in the same census tract 
to which their exemption was attributed.  We selected a maximum cluster size of 50% of 
the population at risk, which would likely capture exemptions assigned to home address 
or school address in the same cluster assuming the two locations were in nearby census 
tracts.  With a smaller setting for maximum cluster size (e.g., 10% of the population at 
risk), some larger exemption clusters were separated into several smaller clusters.  
Notably, the 50% of the population at risk setting is recommended to prevent selection 
bias due to cluster size.
83
  Additionally, the choice to aggregate or not aggregate data 
impacts the total number of exemptions or pertussis cases that are randomly distributed 
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when producing expected data to compare to observed data, which in turn influences the 
statistical significance of clusters.  SaTScan analyses are thus dependent on user settings, 
and results should be interpreted with consideration to these settings.  Our particular 
study design and SaTScan settings were selected under the notion that health departments 
may apply these methods as data become available each year. 
C6. Conclusion 
In conclusion, our study suggests that DTaP exemption clusters identified on an 
annual basis may not identify areas at increased risk of pertussis for the upcoming year if 
the epidemic cycle of pertussis is in a lull.  During high points in the epidemic cycle, the 
risk of pertussis associated with DTaP exemption clusters may be greater than previously 
estimated.  We encourage continued monitoring of this potential trend by state health 
departments.  Given our findings, state health departments may consider monitoring areas 
with exemption clusters to provide increased messaging of pertussis prevention and 
response recommendations to schools, local public health, and healthcare providers when 




D. MANUSCRIPT III 
D1. Objective 
 The study objective is to implement a deterministic compartmental model of 
pertussis transmission in R Studio using Minnesota-specific parameter estimates where 
available.  This transparent model will be used to provide insights into the drivers of local 
outbreaks. 
D2. Introduction 
Models have been increasingly used in efforts to explain the resurgence of 
pertussis in the United States and to inform prevention strategies.
27,28,47
  Infectious 
disease models range from complex predictive models that replicate historic incidence 
trends and forecast future trends, to minimal models that retain only the parameters 
necessary to qualitatively understand disease dynamics.
48,88
  As the complexity of models 
increase, the ability to clearly identify the impact of individual model components on 
population-level dynamics decreases.  While such models are better suited to accurately 
reproduce observed data, they do so at the expense of transparency.
48
  Transparent 
models provide a means to explore the drivers of epidemiologic patterns, with the 
opportunity for additional complexities to be added as underlying dynamics are better 
understood. 
Aguas et al. implemented a minimal model of pertussis transmission in a 
hypothetical population to generate hypotheses regarding the relationship between severe 
disease and transmission frequency.
27
  By only modeling parameters necessary to 
replicate a generic pertussis epidemic, the authors were able to clearly observe the 
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impacts of high and low transmission on the prevalence of severe disease within a 
hypothetical population.  However, because populations have different characteristics – 
some measured (e.g., vaccine uptake, age composition) and some unmeasured (e.g., 
likelihood of seeking treatment) – observed disease dynamics may differ depending on 
the population modeled.
89
  In a review of published pertussis models, Campbell et al. 
noted the importance of using contemporary data relevant to the study population for 
model parameterization whenever possible.
47
  To examine the individual contributions of 
parameters on the epidemic cycle of pertussis in a local setting, we developed a 
compartmental model of pertussis transmission using Minnesota-specific population and 
vaccination estimates.  Case data from the Minnesota Department of Health (MDH) 
served as qualitative calibration targets to inform base estimates of unobservable 
parameters.  We varied parameters estimates over plausible ranges to observe their 
impact on the frequency and magnitude of recurring pertussis outbreaks. 
D3. Research Methods 
D3.1 Model Population 
 The model consisted of seven age groups: 1.) 0-1 year 2.) 2-6 years 3.) 7-10 years 
4.) 11-12 years 5.) 13-21 years 6.) 22-64 years and 7.) 65-100 years.  Age groups were 
based on the pertussis vaccination schedule and contact patterns, with the intent of 
capturing differences in immune status and population mixing by age.  Specifically, the 
child age groups of 2-6 years and 11-12 years represented ages for DTaP and Tdap 
vaccinations, respectively.
11
  The age groups of 22-64 years and 65-100 years were 
selected to differentiate contact patterns between working adults and retired adults.  The 





  The model population was dynamic, with births and age-
dependent deaths (Table 8) reflecting Minnesota rates.
90
  All inputs were converted to 
weekly rates, as each model time step represented one week. 
D3.2 Model Health States 
Individuals in the model were classified as susceptible, infectious, vaccine 
immune, or naturally immune.  Distinct health states existed for naïve (never infected or 
vaccinated) and primed (memory cells that have previously encountered pertussis 
antigen) susceptibility and infectiousness.  The transition diagram in Figure 10 shows 
possible movements between model health states.  The rate at which susceptible 
individuals became infected was dependent on the prevalence of infectious individuals, 
age-specific contacts, and naïve/primed status.  Previously infected or vaccinated 
individuals who returned to the susceptible state were allowed to have a lower likelihood 
of a subsequent infection as compared to naïve susceptible individuals due to a primed 
immune system.
91
  Similarly, primed individuals with a secondary infection were allowed 
to be less infectious than naïve individuals who became infected.  Infected individuals 
were infectious for three weeks before transitioning to a naturally immune state.
6
  We 
assumed that both naturally immune and vaccine immune individuals were fully 
protected from infection for one year, after which immunity began to wane.  Because 
neither pertussis infection nor vaccination induces lifelong immunity, previously immune 
individuals had the opportunity to return to a primed susceptible state.
19
  Conversely, 
individuals with waning immunity also had the opportunity to return to a fully immune 





  Complete model equations and parameter definitions can be found in 
Appendix B. 
D3.3 Model Input Parameters 
D3.3.1 Vaccination Coverage and Efficacy 
 Average National Immunization Surveys (NIS) estimates for Minnesota were 
used to parameterize vaccination coverage for individuals under the age of 18 years.
92
  
NIS coverage estimates are available for children aged 19 to 35 months who have 
received four doses of DTaP or DTP and for adolescents aged 13 to 17 years who have 
received Tdap.  For model parameterization, we assumed that vaccinated individuals 
received vaccines at ages recommended by the Advisory Committee on Immunizations 
Practices schedule.  NIS estimates for DTaP/DTP coverage were applied to individuals in 
the 2-6 year age group.  NIS estimates for adolescent Tdap were applied to individuals in 
the 11-12 year age group.  Behavioral Risk Factor Surveillance System estimates of Tdap 
coverage in adults was applied to the 22-64 and 65-100 year age groups.
93
  The estimates 
for DTaP and Tdap efficacy were both assumed to be 85%.
94
 
D3.3.2 Waning Immunity 
 McGirr et al. conducted a meta-analysis of studies that assessed the long-term 
immunity provided by 5 doses of DTaP.
95
  The reviewed studies varied in design and 
included cohort studies, case-control studies, and a randomized clinical trial.  The 
predicted probability of vaccine failure (i.e., loss of immunity) each year following the 
fifth dose of DTaP was calculated using meta-regression.  McGirr et al. estimated that 
10% of vaccinated children would be immune 8.5 years following their fifth dose of 
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DTaP, assuming an initial vaccine efficacy of 85%.
95
  We assumed that after a maximum 
of 10 years post vaccination with DTaP and in the absence of boosting, immunity waned 
completely and previously vaccinated individuals return to the susceptible health state.  
The duration of waning DTaP immunity was allowed to vary between 1 and 10 years.  
Base estimates for Tdap failure were obtained from a Wisconsin cohort study that used 
surveillance data and vaccination records to estimate vaccine efficacy.
17
  The duration of 
waning Tdap immunity in the absence of boosting was allowed to vary between 1 and 5 
years. 
D3.3.3 Population Mixing 
 We assumed that transmission occurred via age-specific mixing.  Mossong et al. 
conducted a survey to estimate the daily number and type of contacts made by individuals 
of different ages.
96
  Surveys conducted across eight European countries produced similar 
results.  We generated a contact matrix representative of model age groups by averaging 
Mossong et al.'s survey results to estimate the number of age-specific contacts individuals 
were assumed to make each day (Table 9).  Although these data were generated from a 
European population, the pattern of children most frequently coming into contact with 
individuals of the same age and with individuals of a parental age is subjectively in 
agreement with the pattern that would be expected in the United States (i.e., contacts 
made primarily at school and at home). 
D3.3.4 Transmission and Detection 
 Force of infection is defined as the per capita rate at which susceptible individuals 
contract infection.
31
  The rate at which susceptible individuals contract infection is a 
function of the number of infectious individuals in the population and the product of 
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contact rates and transmission probability.  We assumed that transmission probability is 
not age-dependent.  We applied a multiplier to the force of infection for secondary 
exposures, as implemented by Campbell et al., to allow for the possibility of a heightened 
immune response among individuals subject to immune boosting.
47
  The range for this 
multiplier was 1 to 5.  In a previous model, Rohani et al. assumed that 10% of infections 
are detected, which is consistent with CDC estimates of 5-10%.
97,98
  We estimated a 
similar percentage of undetected adult infections in a transmission model of pertussis in a 
metropolitan county in Minnesota.
26
  When varying model parameters, we assumed that 
at most 10% of adult infections were detected, with the potential for greater detection 
among children. 
D3.4 Model Calibration 
  MDH surveillance data (confirmed and probable pertussis cases in Minnesota) 
were used to calibrate the model.  We qualitatively compared model output to weekly 
pertussis prevalence (assumed to be incidence multiplied by duration of infectiousness) in 
Minnesota between 2005 and 2018.  Model parameters were varied across plausible 
ranges during model calibration to obtain a good fit of the model to observed data.  A 
good fit was qualitatively defined as model output that produced 1.) recurring outbreaks 
every 2 to 5 years 2.) outbreaks of similar magnitude to observed data, and 3.) a ratio of 
adult to child pertussis cases similar to observed data (Table 10).  Variations of model 
parameters over plausible ranges were then further explored to observe their impact on 
model output (Table 11).  All models simulations had a fixed burn in period.  Model 




D4.1 Base Case Scenario 
We established a base case scenario that provided a good fit to the data per our 
qualitative criteria.  Recurring peaks occurred roughly every 4 years, with the weekly 
number of prevalent cases ranging from approximately 500 to 1,100 (Figure 11).  The 
average proportion of cases occurring among children each year in the model base case 
was 73%, compared to the annual average of 76% in MDH case data.  Parameter values 
for the base case are listed in Table 13.  The overall percentage of detected infections in 
the base case was 7.6%, with infections among children over 6 times as likely to be 
detected compared to infections among adults.  Children accounted for 29% of total 
infections on average each year in the base case scenario.  In this scenario, the duration of 
naturally acquired immunity was 20 years, and the duration of vaccine acquired 
immunity was 8 years (DTaP) or 4 years (Tdap).  The relative risk of infection among 
primed individuals was 0.75.  In the base case scenario, the rate of transmission did not 
differ between primed and naive infections, and the boosting coefficient was 1. 
D4.2 Exploratory Scenarios 
In comparison to the base case, setting the duration of waning DTaP and Tdap 
immunity to the lower end of their plausible ranges – 1 year – increased the magnitude of 
recurring peaks.  Although the peaks were higher, the difference in case counts between 
high and low points of the cycle was diminished (Figure 12B).  The epidemic cycle was 
not greatly affected by increasing the duration of natural immunity from 20 years to 50 
years (Figure 12C).  Conversely, shortening the duration of natural immunity had an 
effect similar to decreasing the duration of vaccine acquired immunity.  A scenario in 
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which the risk of infection among primed individuals relative to the risk among naïve 
individuals was 50% decreased both the frequency and magnitude of recurring peaks 
(Figure 12D).  The model was sensitive to the boosting coefficient, with a change from 1 
to 2 producing steep peaks and valleys that ranged from approximately 200 prevalent 
cases per week to almost 2,000 prevalent cases per week (Figure 12E).  All scenarios had 
a distribution of cases among children that was similar to the base case scenario. 
D4.2 Trends in Susceptibility 
The susceptible fraction of the population fluctuated around 45% throughout the 
epidemic cycle in most scenarios, including the base case.  The base case susceptible 
fraction consisted largely (approximately 80%) of primed individuals, and on average 
was roughly two thirds adult.  The cyclic pattern of susceptibility among adults did not 
differ from the pattern among children with respect to timing of peaks.  Among adults, 
susceptible individuals were more likely to be primed than naïve, while the inverse was 
true for children.  In the scenario in which transmission from primed infections was half 
as effective as transmission from naive infections (Figure 12F), the susceptible fraction of 
the population fluctuated around 70%.  The scenario with a decreased relative risk of 
infection among primed individuals likewise had an elevated fraction of the susceptible 
population (approximately 60%) relative to the base case. 
D5. Discussion 
 In this study, we implemented a model of pertussis transmission using Minnesota 
data to explore how individual parameters contribute to the epidemic cycle.  Our base 
case scenario suggests that although children account for the majority of detected 
pertussis cases, adults account for the majority of total infections (detected and 
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undetected).  This finding is consistent with adult infections often lacking pertussis 
specific symptoms.
3,4
  The similar temporal patterns of susceptibility among adults and 
children showed no age group driving the epidemic cycle.  These results differ from 
findings by Campbell et al. in which increased prevalence of undetectable antibody levels 
among children was observed to precede an outbreak year in Australia.
38
  Campell et al.’s 
study followed a change to the pertussis vaccination schedule (18 month booster replaced 
with 15-17 year booster), which may have contributed to the observed results.  Worby et 
al. noted that relative to other age groups, 8 to 14 year olds had a larger depletion of their 
susceptible fraction during the ascent of Minnesota’s record outbreak in 2012 and 
therefore had a driving role.
99
  When viewing the percentage change in the susceptible 
population over time in each age group, we did not observe a similar trend.  A possible 
explanation for this difference is the inability of our model to replicate outbreaks in 
specific settings, such as schools, which could be captured in the case data used in the 
study by Worby et al. 
 Our results suggest that the majority of the susceptible population has an immune 
system that has been primed from previous vaccination or infection.  Children were the 
exception to this finding, as they are predominately still under the window of coverage 
from vaccination.  Because of the high level of primed individuals, scenarios in which 
primed infections were not as transmissible as naïve infections severely dampened the 
epidemic cycle and raised the underlying level fraction of the population that was 
susceptible (i.e., lower circulation of pertussis in the population).  The pertussis epidemic 
cycle that we have historically observed may not have been able to persist if infections 
among primed individuals were not as transmissible as infections among naïve 
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individuals.  However, the base case scenario supports the notion that primed individuals 
face a decreased risk of infection upon exposure relative to naïve individuals.
47
  If less 
antigen is necessary for immune boosting than is necessary for a primary infection 
(boosting coefficient > 1), the peaks in the epidemic cycle are more dramatic.  In contrast, 
the cycle is not greatly impacted by prolonging the duration of natural immunity.  
Together, these results show that the opportunity for boosting and loss of immunity 




Assumptions made to simplify the model impact validity and restrict its current 
use.  The broad application of NIS vaccination estimates and the assumption of timely 
vaccine receipt prevented heterogeneity in vaccination coverage (with respect to age, 
geography, or timing) from being represented in the model.  Future iterations of the 
model can be strengthened by the addition of time-varying parameters, expanded age 
groups, and quantitative calibration.  Without these more sophisticated elements, the 
model does not capture cohort effects that may modify the epidemic cycle.
47
  
Additionally, the model does not distinguish between mild or atypical cases and more 
severe cases, which does not allow for exploring potentially differential contributions to 
transmission.
100
  In its current state, the model provides a means to test the influence of 
parameters on a generic pertussis epidemic cycle in a population that has an age 
distribution and vaccine rates similar to Minnesota.  Importantly, the base case scenario 
represents a single parameter set that provides a qualitatively good fit of the model to the 
data.  Other plausible parameter sets that provide a similarly good fit potentially exist, 
particularly if parameters are correlated.  Different parameter sets may result in different 
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conclusions.  If uncertainty in model inputs and outputs are of interest, a more systematic 
calibration approach with a specified search criteria and goodness-of-fit measure could be 
used to identify a collection of top fitting parameter sets. 
D6. Conclusion 
In conclusion, this model represents a foundation to begin exploring drivers of the 
epidemic cycle of pertussis.  With the small proportion of infections that manifest as 
detected cases, relying on cases data to understand trends provides an incomplete picture 




E. GENERAL CONCLUSIONS 
 This dissertation used alternative methods to analyze routinely collected pertussis 
surveillance data and propose supplements to existing surveillance measures as part of 
work to understand the resurgence of pertussis.  The combined results of these analyses 
contribute to identifying opportunities to disrupt the epidemic cycle of pertussis. 
 Manuscript I tested the feasibility of monitoring population immunity through 
serologic testing conducted in a research venue at the Minnesota State Fair.  High 
prevalence of undetectable antibody levels among individuals is an indication of 
increased population susceptibility.  We demonstrated that a sample of 2,000 
Minnesotans of all ages could be tested over the 12 day course of the fair.  The fairground 
setting bypasses many logistical issues that may otherwise prohibit routine 
serosurveillance.  Temporal seroprevalence data can supplement trends in case data and 
vaccine uptake by capturing undetected infections and providing estimates of immunity 
that are subject to waning and immune boosting. 
 In Manuscript II, we used SaTScan software to identify areas in Minnesota where 
children with exemptions to DTaP were spatially clustered.  We assessed the timing of 
these exemption clusters and spatio-temporal pertussis clusters in relation to the epidemic 
cycle of pertussis.  Our key finding was that temporally aggregating exemption data to 
arrive at a single risk estimate may diminish the observed association between exemption 
clusters and pertussis clusters in some years (i.e., high points of the epidemic cycle) while 
overestimating the association in other years (i.e., low points of the epidemic cycle).  This 
association can continue to be measured on an annual basis using data that are collected 
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during pertussis case investigations.  Local public health officials can use this knowledge 
to adapt messaging to potential high risk areas. 
 In manuscript III, we implemented a model of pertussis transmission using 
Minnesota-specific parameters where available.  Modeling provided a means to estimate 
parameters that are not directly observable.  Our results suggested that although children 
account for more detected cases of pertussis, infections are more prevalent among adults.  
Because the majority of the model population had an immune system that was primed 
from previous infection or vaccination, the model was sensitive immune boosting.  The 
model can serve as tool to investigate the impact of different parameters on the frequency 
and magnitude of recurring pertussis outbreaks. 
 In summary, this dissertation used serologic, spatial, and modeling techniques to 
identify opportunities to reduce the occurrence of pertussis, a vaccine-preventable disease 
that has reestablished itself as a public health concern.  The continued use of these 
research methods will contribute to reducing the knowledge gaps that exist in our 
understanding of the pertussis epidemic cycle. 
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Table 1. Interpretation of IgG anti-PT ELISA results  
IgG ELISA result Interpretation 
<5 IU/mL Undetectable (susceptible) 
5 - 62.5 IU/mL Non-recent vaccination or infection with pertussis 
> 62.5 IU/mL Recent* vaccination or infection with pertussis 




Table 2.  Enrollment numbers for pilot study and projection to future studies 
  Pilot study Future study 
Total participants 104 1200 
Study duration (days)* 3 12 
Recruitment rate (participants/hour) 5.8 16.7 










2016 ACS (%) 
Age group 
       1 to 6 years 18 (17.3%) N/A* 
     7 to 17 years 53 (51.0%) N/A* 
     18+ years 33 (31.7%) N/A* 
Race 
       American Indian or Alaskan Native 0 (0.0%) 1.1% 
     Asian 2 (1.9%) 4.7% 
     Black or African American 4 (3.9%) 6.0% 
     Hawaiian or Other Pacific Islander 0 (0.0%) 0.0% 
     White 88 (84.6%) 83.3% 
     Multiracial 6 (5.8%) 2.8% 
     Other 3 (2.9%) 2.0% 
     Unknown 1 (1.0%) 0.0% 
Ethnicity 
       Hispanic or Latino 7 (6.7%) 5.2% 
     Not Hispanic or Latino 95 (91.3%) 94.8% 
     Unknown 2 (1.9%) 0.0% 
Highest level of education completed 
       ≤ High school diploma or GED 69 (66.3%) N/A* 
     High school diploma or GED 14 (13.5%) N/A* 
     Associate's or Bachelor's degree 13 (12.5%) N/A* 
     Graduate or professional degree 5 (4.8%) N/A* 
      Unknown 3 (2.9) N/A* 
Metropolitan resident 
     Yes 68 (65.4%) 55.0% 
     No 33 (31.7%) 45.0% 
     Unknown 3 (2.9%) 0.0% 
Gender 
        Female 60 (57.7%) 50.2% 
      Male 44 (42.3%) 49.8% 
*Study data not compared to Minnesota population due to age-stratified 




Table 4. Annual spatial clusters of DTaP exemptions among  




Exemptions Population RR 
School 
Year 
62 4.08 177 15.74 2012-2013 
381 273.11 11,834 1.51 2012-2013 
329 233.3 10,109 1.51 2012-2013 
16 3.95 171 4.08 2012-2013 
149 102.01 4,420 1.51 2012-2013 
77 44.68 1,936 1.76 2012-2013 
208 130.38 5,028 1.67 2013-2014 
15 1.69 65 8.97 2013-2014 
248 169.45 6,535 1.54 2013-2014 
58 24.97 963 2.37 2013-2014 
26 7.26 280 3.62 2013-2014 
31 10.99 424 2.85 2013-2014 
10 1.4 54 7.18 2013-2014 
4 0.1 4 38.65 2013-2014 
655 477.26 19,334 1.62 2014-2015 
14 1.14 46 12.43 2014-2015 
5 0.12 5 40.63 2014-2015 
158 105.6 4,278 1.55 2014-2015 
34 5.71 211 6.05 2015-2016 
436 307.8 11,381 1.55 2015-2016 
13 1.24 45 10.52 2015-2016 
17 2.62 97 6.53 2015-2016 












tracts RR Start Date End Date 
168 13.32 166,576 37 13.2 04/01/2016 09/30/2016 
190 50.75 276,625 62 3.9 10/01/2013 11/30/2014 
26 0.18 4,663 1 143.9 02/01/2016 04/30/2016 
60 5.12 77,598 21 11.9 07/01/2013 11/30/2013 
28 0.44 8,231 2 64.7 04/01/2013 07/31/2013 
72 8.95 61,043 14 8.2 09/01/2015 07/31/2016 
31 1.48 16,191 3 21.2 06/01/2016 12/31/2016 
164 64.90 1,606,725 364 2.6 10/01/2016 12/31/2016 





Table 6. Association between census tract demographic variables and clusters of 




OR (95% CI) 
Pertussis cluster 
OR (95% CI) 
Percent non-white 0.96 (0.95, 0.97) 1.02 (1.01, 1.02) 
Percent Hispanic or Latino 0.86 (0.83, 0.89) 1.00 (0.98, 1.02) 
Percent less than high school degree 0.96 (0.94, 0.97) 0.96 (0.94, 0.98) 
Percent of households with income 
over $100,000 
1.01 (1.00, 1.02) 1.03 (1.02, 1.04) 










0-1 year 2.7% 
2 -6 years 6.6% 
7-10 years 5.3% 
11 -12 years 2.7% 
13-21 years 12.3% 
22-64 years 57.4% 





Table 8. Model death rates  




0-1 year 0.0000446 
2-6 years 0.0000038 
7 -10 years 0.0000025 
11-12 years 0.0000027 
13-21 years 0.0000084 
22-64 years 0.0000501 





Table 9. Average number of age-dependent contacts (physical or non-physical)  
assumed each day for model simulations 
Age group 0-1 2-6 7-10 11-12 13-21 22-64 65-100 
0-1 year 0.95 1.78 0.59 0.11 0.40 3.67 0.75 
2-6 years 0.76 2.42 2.04 0.25 0.60 3.94 0.81 
7-10 years 0.40 2.73 3.83 1.27 1.98 4.35 0.95 
11-12 years 0.18 0.80 2.65 3.72 5.21 4.33 1.12 
13-21 years 0.13 0.41 0.93 1.22 7.59 6.36 1.13 
22-64 years 0.25 0.65 0.52 0.25 1.42 8.96 2.32 





Table 10. Age distribution of confirmed  
and probable pertussis cases in Minnesota 
Year 
Percentage of 




2005 32% 68% 
2006 28% 72% 
2007 28% 72% 
2008 23% 77% 
2009 20% 80% 
2010 26% 74% 
2011 22% 78% 
2012 21% 79% 
2013 22% 78% 
2014 18% 82% 
2015 22% 78% 
2016 24% 76% 
2017 25% 75% 
2018 23% 77% 






Table 11. Variable model parameters 
Parameter Base case Plausible range 
Duration of waning natural immunity 20 years 1 to 50 years 
Duration of waning DTaP immunity 8 years 1 to 10 years 
Duration of waning Tdap immunity 4 years 1 to 5 years 
Transmission rate for primary infections 0.03 0.01 to 0.5 
Transmission rate for secondary infections 0.03 0.01 to 0.5 
Relative risk of infection among primed individuals 0.75 0 to 1 
Boosting coefficient 1 1 to 5 
Percentage of adult infections detected 3% 1% to 10% 
























































































































































































































































     Figure 6. National Immunization Survey estimated percentage of  































































































    Figure 7. IgG anti-PT antibody levels (IU/mL) in 2016 























Figure 8. Spatiotemporal pertussis clusters in Minnesota relative to spatial DTaP 
exemption clusters identified from annual AISR kindergarten data A) 2012-2013 
exemption and 2013 pertussis clusters B) 2013-2014 exemption and 2014 pertussis 
clusters C) 2014-2015 exemption and 2015 pertussis clusters D) 2015-2016 exemption 
and 2016 pertussis clusters.  The insert shows a 2015 pertussis cluster in the Minneapolis-





Figure 9. Depiction of cluster identification with cases aggregated at the county level A.) 
Cases within the scan window but in a county with a geographic center outside of the 
scan window are not part of the cluster.  B.) Cases in counties with a geographic center in 







Figure 10. Transition diagram of compartmental pertussis model.  Deaths can occur from 









Figure 12. Comparison of model base case scenario to exploratory scenarios A) base 
case B) 1 year waning vaccine immunity C) 50 year natural immunity D) relative risk of 
infection among primed individuals is 0.5 E) boosting coefficient is 2 F.) primed 
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